

CORRECTION

Open Access



Correction to: Reversibility of motor dysfunction in the rat model of NGLY1 deficiency

Makoto Asahina^{1,3}, Reiko Fujinawa^{2,3}, Hiroto Hirayama^{2,3}, Ryuichi Tozawa^{1,3}, Yasushi Kajii¹ and Tadashi Suzuki^{2,3*}

Correction to: *Mol Brain* (2021) 14:91

<https://doi.org/10.1186/s13041-021-00806-6>

Following publication of the original article [1], the authors would like to correct 2 errors in the "Methods" section.

The first sentence in the "Preparation of cytosolic fraction and enrichment of NGLY1" subsection originally read:

For preparation of lysate, 50 mg of rat brain was sliced and resuspended in 500 μ l NGLY1 buffer (5 mM Tris-HCl; pH 7.5), 250 mM glycerol, 1 mM PefablocTMSC (Sigma-Aldrich; 11429868001), and 1 \times cCompleteTM protease inhibitor cocktail (Sigma-Aldrich; 11836145001).

The sentence should read (the change has been highlighted in **bold typeface**):

For preparation of lysate, 50 mg of rat brain was sliced and resuspended in 500 μ l NGLY1 buffer (**100** mM Tris-HCl; pH 7.5, 250 mM **sucrose**, 1 mM PefablocTMSC (Sigma-Aldrich; 11429868001), and 1 \times cCompleteTM protease inhibitor cocktail (Sigma-Aldrich; 11836145001)).

The second sentence in the "Activity assay of the enriched NGLY1 fraction" section originally read:

Briefly, the reaction mixture containing 25 μ l of the NGLY1 fraction in a total volume of 30 μ l of 10 mM Tris-HCl (pH 7.5), 50 mM sucrose, 1 mM DTT, 1 mM PefablocTM SC, and 1 \times cCompleteTM protease inhibitor cocktail (EDTA-free) together with 53 pmol of BODIPY-asialoglycopeptide (BODIPY-ASGP) was incubated at 25 $^{\circ}$ C for 6 h.

The second sentence should read (the change has been highlighted in **bold typeface**):

Briefly, the reaction mixture containing 25 μ l of the NGLY1 fraction in a total volume of 30 μ l **containing** 1 mM DTT, 1 mM PefablocTM SC, and 1 \times cCompleteTM protease inhibitor cocktail (EDTA-free) together with 53 pmol of BODIPY-asialoglycopeptide (BODIPY-ASGP) was incubated at 25 $^{\circ}$ C for 6 h.

These errors do not affect any of the conclusions presented in the article. The original article [1] has been corrected.

The original article can be found online at <https://doi.org/10.1186/s13041-021-00806-6>.

*Correspondence: tsuzuki_gm@riken.jp

² Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
Full list of author information is available at the end of the article



Author details

¹T-CiRA Discovery, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 2518555, Japan. ²Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. ³Takeda-CiRA Joint Program (T-CiRA), Fujisawa, Kanagawa 2518555, Japan.

Published online: 16 August 2021

Reference

1. Asahina M, Fujinawa R, Hirayama H, Tozawa R, Kajii Y, Suzuki T. Reversibility of motor dysfunction in the rat model of NGLY1 deficiency. *Mol Brain*. 2021;14:91. <https://doi.org/10.1186/s13041-021-00806-6>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

